The differential effects of green tea on dose-dependent doxorubicin toxicity

References

• Fulbright JM. Review of cardiotoxicity in pediatric cancer patients: during and after therapy. Cardiol Res Pract. 2011; 2011: 942090.
   PubMedGoogle Scholar
• Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, etal. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol. 2011; 148: 194–8.
   PubMed Web of Science ®Google Scholar
• Dudka J, Burdan F, Korga A, Dyndor K, Syroka I, Zieba J, etal. The diagnosis of anthracycline-induced cardiac damage and heart failure. Postepy Hig Med Dosw. 2009; 63: 225–33.
   Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991; 266: 1672–7.
   PubMed Web of Science ®Google Scholar
• Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001; 19: 191–6.
   PubMed Web of Science ®Google Scholar
• Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, etal. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131: 1981–8.
   PubMed Web of Science ®Google Scholar
• Christiansen S, Autschbach R. Doxorubicin in experimental and clinical heart failure. Eur J Cardiothorac Surg. 2006; 30: 611–16.
   PubMed Web of Science ®Google Scholar
• Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973; 32: 302–14.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004; 56: 185–229.
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Res. 1983; 43: 460–72.
   PubMed Web of Science ®Google Scholar
• Sarvazyan N. Visualization of doxorubicin-induced oxidative stress in isolated cardiac myocytes. Am J Physiol. 1996; 271: 2079–85.
   PubMed Web of Science ®Google Scholar
• Doroshow JH. Anthracycline antibiotic-stimulated superoxide, hydrogen peroxide, and hydroxyl radical production by NADH dehydrogenase. Cancer Res. 1983; 43: 4543–51.
   PubMed Web of Science ®Google Scholar
• Vásquez-Vivar J, Martasek P, Hogg N, Masters BS, Pritchard KA, Kalyanaraman B. Endothelial nitric oxide synthase-dependent superoxide generation from adriamycin. Biochemistry. 1997; 36: 11293–7.
   PubMed Web of Science ®Google Scholar
• Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of mtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003; 108: 2423–9.
   PubMed Web of Science ®Google Scholar
• Lebrecht D, Walker UA. Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007; 7: 108–13.
   PubMed Web of Science ®Google Scholar
• Lebrecht D, Kirschner J, Geist A, Haberstroh J, Walker UA. Respiratory chain deficiency precedes the disrupted calcium homeostasis in chronic doxorubicin cardiomyopathy. Cardiovasc Pathol. 2010; 19: e167–74.
   Google Scholar
• Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014; 34: 106–35.
   PubMed Web of Science ®Google Scholar
• Chen Y, Saari JT, Kang YJ. Weak antioxidant defenses make the heart a target for damage in copper-deficient rats. Free Radic Biol Med. 1994; 17: 529–36.
   PubMed Web of Science ®Google Scholar
• Julicher RH, Sterrenberg L, Haenen GR, Bast A, Noordhoek J. The effect of chronic adriamycin treatment on heart kidney and liver tissue of male and female rat. Arch Toxicol. 1988; 61: 275–81.
   Web of Science ®Google Scholar
• Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest. 1980; 65: 128–35.
   PubMed Web of Science ®Google Scholar
• Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol. 2003; 3: 89–99.
   PubMedGoogle Scholar
• Kim DS, Woo ER, Chae SW, Ha KC, Lee GH, Hong ST, etal. Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-kappaB activation. Life Sci. 2007; 80: 314–23.
   PubMed Web of Science ®Google Scholar
• Ashour AE, Sayed-Ahmed MM, Abd-Allah AR, Korashy HM, Maayah ZH, Alkhalidi H, etal. Metformin rescues the myocardium from doxorubicin-induced energy starvation and mitochondrial damage in rats. Oxid Med Cell Longev. 2012; 2012: 434195.
   Google Scholar
• Hrelia S, Bordoni A, Angeloni C, Leoncini E, Toschi TG, Lercker G, etal. Green tea extracts can counteract the modification of fatty acid composition induced by doxorubicin in cultured cardiomyocytes. Prostaglandins Leukot Essent Fatty Acids. 2002; 66: 519–24.
   Web of Science ®Google Scholar
• Hrelia S, Fiorentini D, Maraldi T, Angeloni C, Bordoni A, Biagi PL, etal. Doxorubicin induces early lipid peroxidation associated with changes in glucose transport in cultured cardiomyocytes. Biochim Biophys Acta. 2002; 1567: 150–6.
   PubMed Web of Science ®Google Scholar
• Segredo MP, Salvadori DM, Rocha NS, Moretto FC, Correa CR, Camargo EA, etal. Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin. Hum Exp Toxicol. 2014; 33: 748–60.
   PubMed Web of Science ®Google Scholar
• Segura AM, Radovancevic R, Demirozu ZT, Frazier OH, Buja LM. Anthracycline treatment and ventricular remodeling in left ventricular assist device patients. Tex Heart Inst J. 2015; 42: 124–30.
   Web of Science ®Google Scholar
• Dudka J, Jodynis-Liebert J, Korobowicz E, Burdan F, Korobowicz A, Szumilo J, etal. Activity of NADPH-cytochrome P-450 reductase of the human heart, liver and lungs in the presence of (-)-epigallocatechin gallate, quercetin and resveratrol: an in vitro study. Basic Clin Pharmacol Toxicol. 2005; 97: 74–9.
   Web of Science ®Google Scholar
• Dudka J. Decrease in NADPH-cytochrome P450 reductase activity of the human heart, liver and lungs in the presence of alpha-lipoic acid. Ann Nutr Metab. 2006; 50: 121–5.
   Web of Science ®Google Scholar
• Chen RC, Xu XD, Zhi Liu X, Sun GB, Zhu YD, Dong X, etal. Total flavonoids from Clinopodium chinense (Benth.) O. Ktze protect against doxorubicin-induced cardiotoxicity in vitro and in vivo. Evid Based Complement Alternat Med. 2015; 2015: 472565.
   PubMed Web of Science ®Google Scholar
• Chularojmontri L, Gerdprasert O, Wattanapitayakul SK. Pummelo protects doxorubicin-induced cardiac cell death by reducing oxidative stress, modifying glutathione transferase expression, and preventing cellular senescence. Evid Based Complement Alternat Med. 2013; 2013: 254835.
   Google Scholar
• Afzal M, Safer AM, Menon M. Green tea polyphenols and their potential role in health and disease. Inflammopharmacology. 2015; 23: 151–61.
   PubMed Web of Science ®Google Scholar
• Sano M, Takahashi Y, Yoshino K, Shimoi K, Nakamura Y, Tomita I, etal. Effect of tea (Camellia sinensis L.) on lipid peroxidation in rat liver and kidney: a comparison of green and black tea feeding. Biol Pharm Bull. 1995; 18: 1006–8.
   PubMed Web of Science ®Google Scholar
• Sarma DN, Barrett ML, Chavez ML, Gardiner P, Ko R, Mahady GB, etal. Safety of green tea extracts: a systematic review. US Pharmacopeia Drug Saf. 2008; 31: 469–84.
   PubMed Web of Science ®Google Scholar
• Graham HN. Green tea composition, consumption, and polyphenol chemistry. Prev Med. 1992; 21: 334–50.
   PubMed Web of Science ®Google Scholar
• Alschuler L. Green tea: healing tonic. Am J Natur Med. 1998; 5: 28–31.
   Google Scholar
• Mandel SA, Amit T, Kalfon L, Reznichenko L, Weinreb O, Youdim MB. Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG). J Alzheimers Dis. 2008; 15: 211–22.
   PubMed Web of Science ®Google Scholar
• Serafini M, Ghiselli A, Ferro-Luzzi A. In vitro antioxidant effect of green and black tea in man. Eur J Clin Nutr. 1996; 50: 28–32.
   PubMed Web of Science ®Google Scholar
• Erba D, Riso P, Colombo A, Testalin G. Supplementation of Jurkat T cells with green tea extract decreases oxidative damage due to iron treatment. J Nutr. 1999; 129: 2130–4.
   Web of Science ®Google Scholar
• Abe I, Seki T, Umehara K, Miyase T, Noguchi H, Sakakibara J, etal. Green tea polyphenols: novel and potent inhibitors of squalene epoxidase. Biochem Biophys Res Commun. 2000; 268: 767–71.
   PubMed Web of Science ®Google Scholar
• Lee SM, Kim CW, Kim JK, Shin HJ, Baik JH. GCG-rich tea catechins are effective in lowering cholesterol and triglyceride concentrations in hyperlipidemic rats. Lipids. 2008; 43: 419–29.
   PubMed Web of Science ®Google Scholar
• Li W, Nie S, Xie M, Chen Y, Li C, Zhang H. A major green tea component, (-)-epigallocatechin-3-gallate ameliorates doxorubicin-mediated cardiotoxicity in cardiomyocytes of neonatal rats. J Agric Food Chem. 2010; 58: 8877.
   Web of Science ®Google Scholar
• Khan G, Haque SE, Anwer T, Ahsan MN, Safhi MM, Alam MF. Cardioprotective effect of green tea extract on doxorubicin-induced cardiotoxicity in rats. Acta Pol Pharm. 2014; 71: 861–8.
   PubMed Web of Science ®Google Scholar
• Saeed NM, El-Naga RN, El-Bakly WM, Abdel-Rahman HM, Salah El-Din RA, El-Demerdash E. Epigallocatechin-3-gallate pretreatment attenuates doxorubicin-induced cardiotoxicity in rats: a mechanistic study. Biochem Pharmacol. 2015; 95: 145–55.
   PubMed Web of Science ®Google Scholar
• Korga A, Dudka J, Burdan F, Sliwinska J, Mandziuk S, Dawidek-Pietryka K. The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and doxorubicin. Oxid Med Cell Longev. 2012; 2012: 681367.
   Google Scholar
• Sliwinska J, Dudka J, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, etal. Tirapazamine-doxorubicin interaction referring to heart oxidative stress and Ca2+ balance protein levels. Oxid Med Cell Longev. 2012; 2012: 890826.
   Google Scholar
• Dudka J, Gieroba R, Korga A, Burdan F, Matysiak W, Jodlowska-Jedrych B, etal. Different effects of resveratrol on dose-related doxorubicin-induced heart and liver toxicity. Evid Based Complement Alternat Med. 2012; 2012: 606183.
   PubMed Web of Science ®Google Scholar
• Dudka J, Mandziuk S, Madej-Czerwonka B, Sierocińska-Sawa J, Walczyna B, Korga A, etal. Effect of iodothyronine hormone status on doxorubicin related cardiotoxicity. Folia Morphol (Warsz). 2013; 72: 340–8.
   Web of Science ®Google Scholar
• Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007; 23: 15–25.
   PubMed Web of Science ®Google Scholar
• Mandziuk S, Czubara U, Korga A, Madej-Czerwonak B, Cendrowska-Pinkosz M, Dudka J. Effect of thyroxine on cardiac GLUT4 changes induced by doxorubicin. Curr Iss Pharm Med Sci. 2013; 26: 331–4.
   Google Scholar
• Lemasters JJ, Nieminen AL. Mitochondria in pathogenesis. 2001; New York: Kluwer Academic. 53–80.
   Google Scholar
• Takimoto E, Kass DA. Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 2007; 49: 241–8.
   PubMed Web of Science ®Google Scholar
• Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, etal. Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol. 2010; 66: 303–14.
   PubMed Web of Science ®Google Scholar
• Tsutsui H, Kinugawa S, Matsushima S. Mitochondrial oxidative stress and dysfunction in myocardial remodelling. Cardiovasc Res. 2009; 81: 449–56.
   PubMed Web of Science ®Google Scholar
• Mross K, Maessen P, van der Vijgh WJ, Gall H, Boven E, Pinedo HM. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans. J Clin Oncol. 1988; 6: 517–26.
   PubMed Web of Science ®Google Scholar
• Robert J, Vrignaud P, Nguyen-Ngoc T, Iliadis A, Mauriac L, Hurteloup P. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer. Cancer Treat Rep. 1985; 69: 633–40.
   Google Scholar
• Shen FF, Jiang TH, Jiang JQ, Lou Y, Hou XM. Traditional Chinese medicine tongxinluo improves cardiac function of rats with dilated cardiomyopathy. Evid Based Complement Alternat Med. 2014; 2014: 323870.
   Google Scholar
• Dhingra R, Margulets V, Chowdhury SR, Thliveris J, Jassal D, Fernyhough P, etal. Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling. Proc Natl Acad Sci USA. 2014; 111: E5537–44.
   PubMed Web of Science ®Google Scholar
• Gao Y, Xu Y, Hua S, Zhou S, Wang K. ALDH2 attenuates Dox-induced cardiotoxicity by inhibiting cardiac apoptosis and oxidative stress. Int J Clin Exp Med. 2015; 8: 6794–803.
   PubMed Web of Science ®Google Scholar
• Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, Kotamraju S. Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem. 2002; 234–5: 119–24.
   Web of Science ®Google Scholar
• Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K, Colucci WS. Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 2002; 34: 379–88.
   PubMed Web of Science ®Google Scholar
• Cribb AE, Peyrou M, Muruganandan S, Schneider L. The endoplasmic reticulum in xenobiotic toxicity. Drug Metab Rev. 2005; 37: 405–42.
   PubMed Web of Science ®Google Scholar
• Berthiaume JM, Wallace KB. Persistent alterations to the gene expression profile of the heart subsequent to chronic doxorubicin treatment. Cardiovasc Toxicol. 2007; 7: 178–91.
   Web of Science ®Google Scholar
• Wnukowska M, Mandziuk S, Korga A, Jodlowska-Jedrych B, Matysiak W, Halasa J, etal. The effect of one-electron reduced drugs on hepatic aconitase activity and triglycerides level. Curr Iss Pharm Med Sci. 2015; 28: 5–7.
   Web of Science ®Google Scholar
• Czuba B, Fituch M, Mandziuk S, Jodlowska-Jedrych B, Matysiak W, Halasa J, etal. The effect of thyroxin on hepatic redox equilibrium and lipid metabolism in rats treated with doxorubicin. Curr Iss Pharm Med Sci. 2014; 27: 220–3.
   Google Scholar
• Chow HH, Cai Y, Hakim IA, Crowell JA, Shahi F, Brooks CA, etal. Pharmacokinetics and safety of green tea polyphenols after multipledose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res. 2003; 9: 3312–19.
   PubMed Web of Science ®Google Scholar
• Zheng J, Lee HC, Bin Sattar MM, Huang Y, Bian JS. Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. Eur J Pharmacol. 2011; 652: 82–8.
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Al-Shabanah OA, Hafez MM, Aleisa AM, Al-Rejaie SS. Inhibition of gene expression of heart fatty acid binding protein and organic cation/carnitine transporter in doxorubicin cardiomyopathic rat model. Eur J Pharmacol. 2010; 640: 143–9.
   Web of Science ®Google Scholar
• Cuccioloni M, Mozzicafreddo M, Spina M, Tran CN, Falconi M, Eleuteri AM, etal. Epigallocatechin-3-gallate potently inhibits the in vitro activity of hydroxy-3-methyl-glutaryl-CoAreductase. J Lipid Res. 2011; 52: 897–907.
   PubMed Web of Science ®Google Scholar